Rinonorm Teva spray 0.1%, 20 ml

Rinonorm is used as symptomatic therapy for the following diseases and conditions:

acute viral or bacterial rhinitis;

acute allergic rhinitis;

acute sinusitis or exacerbation of chronic sinusitis;

acute otitis media (to reduce swelling of the mucous membrane of the Eustachian tube);

preparation of the patient for diagnostic procedures in the nasal passages.

Adults and children over 10 years of age are prescribed Rinonorm nasal spray 0.1% in 1 dose (1 press on the piston device) in each nasal passage no more than 3 times / day.

Children aged 2 to 10 years are prescribed Rinonorm nasal spray for children 0.05%, 1 dose (1 press on the piston device) in each nasal passage no more than 3 times / day.

The maximum possible use of the drug is no more than 7 times / day. The interval between the administration of the drug should not be less than 6 hours. The amount of fluid entering the patient's nasal passage (1 dose) is equal to 0.14 ml of solution.

In order to avoid complications in the form of a recurrence of the symptoms of the disease, the duration of continuous use of the drug should not exceed 7 days. Before using the drug, you should free the nasal passages from the secretion. During the administration of the drug, a light breath should be taken through the nose.

xylometazoline hydrochloride

Excipients: citric acid monohydrate, sodium citrate dihydrate, glycerol 85%, water d / i.

• atrophic (dry) rhinitis;

• angle-closure glaucoma;

• condition after hypophysectomy;

• concomitant use of MAO inhibitors and tricyclic antidepressants;

• children under 2 years of age (for spray for children);

• children under 10 years of age (for adult spray);

• hypersensitivity to xylometazoline or other components of the drug.

• The drug should be used with caution in arterial hypertension, severe heart disease, hyperthyroidism, diabetes mellitus and in patients taking bromocriptine.

pharmachologic effect

Alpha-adrenergic agonist for topical use in ENT practice. When applied topically, xylometazoline causes narrowing of arterioles, leads to a decrease in hyperemia and edema of the mucous membranes of the nasopharynx and a decrease in secretion. A distinct local effect of the drug is detected within a few minutes and lasts for several hours (up to 6-8 hours), manifesting itself in the restoration of patency of the nasal passages, openings of the sinuses and Eustachian tubes. Restoring air permeability of the nasopharynx improves the patient's well-being and reduces the risk of possible complications caused by stagnation of mucous secretions.

Pharmacokinetics

When applied topically, xylometazoline is practically not absorbed, therefore, plasma concentrations are very small (not analytically determined).

Side effect

Local reactions: burning sensation and dryness of the nasal mucosa; rarely - irritation of the nasal mucosa, mouth and larynx. From the side of the central nervous system: rarely - headache; extremely rare (<1/10 000) - insomnia, hyperexcitability. From the side of the cardiovascular system: extremely rare (<1/10 000) - arrhythmia, increased blood pressure. Others: rarely - nausea; extremely rare (<1/10 000) - skin reactions.

Application during pregnancy and lactation

The drug should not be taken during pregnancy. The drug should be used with caution during breastfeeding.

special instructions

Influence on the ability to drive vehicles and use mechanisms

No influence on the ability to drive vehicles and on the control of machines and mechanisms was noted.

Overdose

Symptoms: in rare cases of overdose, occurring mainly in children, arrhythmia, increased blood pressure, and, in some cases, loss of consciousness may occur. Treatment: symptomatic therapy is indicated under supervision. In severe cases, non-selective alpha-blockers can be used to lower blood pressure, as well as intubation and mechanical ventilation. Vasoconstrictor drugs are contraindicated. If you accidentally take a moderate or large amount of the drug inside, you should take activated charcoal and a laxative (for example, sodium sulfate), do a gastric lavage.

Drug interactions

Concomitant use of tri- or tetracyclic antidepressants may increase the systemic exposure to xylometazoline. With the simultaneous administration of the drug with MAO inhibitors, the risk of an increase in blood pressure is possible.